Dr. Claire Clibborn, Dr. Erman Güler, Prof. Andrew Alexis,
18 Oct 2023
Janus kinase (JAK) inhibition has emerged as a novel approach in systemic treatment of moderate-to-severe atopic dermatitis (AD). This article summarizes results of select phase III studies of the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) global development programme investigating the safety and efficacy of abrocitinib, a selective JAK1 inhibitor, in patients with moderate-to-severe AD, which were presented at the 25th World Congress of Dermatology (WCD) held in Singapore.